Hologic’s Genius Digital Diagnostics System Receives the US FDA’s Clearance to Identify Pre-Cancerous Lesions
Shots:
- The US FDA has cleared Hologic's Genius Digital Diagnostics System that links AI with volumetric imaging technology to diagnose pre-cancerous lesions and cervical cancer cells. It is available in the EU, Australia & New Zealand while its US commercial availability is anticipated in early 2024
- The system includes Genius Digital Imager for acquiring images, Genius Cervical AI algorithm to analyze images, Genius Image Management Server for storing images and Genius Review Station for reviewing local or remote cases
- Moreover, unlike conventional pap tests, this system screens the patient's samples digitally using an AI algorithm to identify the cells to be reviewed by cytologists and pathologists
Ref: Hologic | Image: Hologic
Related News:- Vistagen Reports P-III Trial (PALISADE-2) Results of Fasedienol (PH94B) Nasal Spray for Social Anxiety Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
